X. Rebillard, P. Grosclaude, N. Leone, M. Velten, G. Coureau et al., Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2012, Progr??s en Urologie, vol.23, issue.2, pp.57-65, 2013.
DOI : 10.1016/S1166-7087(13)70047-2

P. Moran, O. Neill, M. Teljeur, C. Flattery, M. Murphy et al., Robotassisted radical prostatectomy compared with open and laparoscopic approaches: a systematic review and meta-analysis, International journal of urology : official journal of the Japanese Urological Association, vol.2013, issue.203, pp.312-321

A. Bill-axelson, L. Holmberg, H. Garmo, J. Rider, K. Taari et al., Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer, New England Journal of Medicine, vol.370, issue.10, pp.370932-942
DOI : 10.1056/NEJMoa1311593

M. Han, A. Partin, C. Pound, J. Epstein, and P. Walsh, LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY, Urologic Clinics of North America, vol.28, issue.3, pp.555-565, 2001.
DOI : 10.1016/S0094-0143(05)70163-4

A. Stephenson, M. Kattan, J. Eastham, F. Bianco, J. Yossepowitch et al., Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, issue.26, pp.274300-4305, 2009.

C. Porter, K. Kodama, R. Gibbons, R. Correa, J. Chun et al., 25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution Series, The Journal of Urology, vol.176, issue.2, pp.569-574, 2006.
DOI : 10.1016/j.juro.2006.03.094

M. Menon, M. Bhandari, N. Gupta, Z. Lane, J. Peabody et al., Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-year Follow-up, European Urology, vol.58, issue.6, pp.58838-846, 2010.
DOI : 10.1016/j.eururo.2010.09.010

N. Suardi, V. Ficarra, P. Willemsen, D. Wil, P. Gallina et al., Long-term Biochemical Recurrence Rates After Robot-assisted Radical Prostatectomy: Analysis of a Single-center Series of Patients With a Minimum Follow-up of 5 Years, Urology, vol.79, issue.1, pp.133-138
DOI : 10.1016/j.urology.2011.08.045

V. Ficarra, G. Novara, R. Rosen, W. Artibani, P. Carroll et al., Systematic Review and Meta-analysis of Studies Reporting Urinary Continence Recovery After Robot-assisted Radical Prostatectomy, European Urology, vol.62, issue.3, pp.62405-417
DOI : 10.1016/j.eururo.2012.05.045

V. Ficarra, G. Novara, T. Ahlering, A. Costello, J. Eastham et al., Systematic Review and Meta-analysis of Studies Reporting Potency Rates After Robot-assisted Radical Prostatectomy, European Urology, vol.62, issue.3, pp.62418-430
DOI : 10.1016/j.eururo.2012.05.046

S. Hummel, E. Simpson, P. Hemingway, M. Stevenson, and A. Rees, Intensitymodulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation, Health technology assessment, vol.14, issue.47, pp.1-108, 2010.

D. Kuban, L. Levy, M. Cheung, A. Lee, S. Choi et al., Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?, Int J Radiat Oncol Biol Phys, issue.5, pp.791310-1317, 2011.

M. Zelefsky, X. Pei, J. Chou, M. Schechter, M. Kollmeier et al., Dose Escalation for Prostate Cancer Radiotherapy: Predictors of Long-Term Biochemical Tumor Control and Distant Metastases???Free Survival Outcomes, European Urology, vol.60, issue.6, pp.601133-1139, 2011.
DOI : 10.1016/j.eururo.2011.08.029

S. Peeters, W. Heemsbergen, P. Koper, W. Van-putten, A. Slot et al., Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy, Journal of Clinical Oncology, vol.24, issue.13, pp.241990-1996, 2006.
DOI : 10.1200/JCO.2005.05.2530

C. Jones, D. Hunt, D. Mcgowan, M. Amin, M. Chetner et al., Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer, New England Journal of Medicine, vol.365, issue.2, pp.107-118, 2011.
DOI : 10.1056/NEJMoa1012348

D. Dearnaley, G. Jovic, I. Syndikus, V. Khoo, R. Cowan et al., Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial, The Lancet Oncology, vol.15, issue.4, pp.464-473, 2014.
DOI : 10.1016/S1470-2045(14)70040-3

M. Abramowitz, T. Li, M. Buyyounouski, E. Ross, R. Uzzo et al., The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer, Cancer, vol.53, issue.1, pp.55-60, 2008.
DOI : 10.1002/cncr.23139

M. Zelefsky, K. Wallner, C. Ling, A. Raben, T. Hollister et al., Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer, Journal of Clinical Oncology, vol.17, issue.2, pp.517-522, 1999.
DOI : 10.1200/JCO.1999.17.2.517

J. Huang, L. Kestin, H. Ye, M. Wallace, A. Martinez et al., Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, pp.81-86, 2011.

P. Bostrom and M. Soloway, Secondary Cancer After Radiotherapy for Prostate Cancer: Should We Be More Aware of the Risk?, European Urology, vol.52, issue.4, pp.973-982, 2007.
DOI : 10.1016/j.eururo.2007.07.002

A. Heidenreich, P. Bastian, J. Bellmunt, M. Bolla, S. Joniau et al., EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent???Update 2013, European Urology, vol.65, issue.1, pp.124-137
DOI : 10.1016/j.eururo.2013.09.046

M. Zelefsky, D. Kuban, L. Levy, L. Potters, D. Beyer et al., Multi-institutional analysis of long-term outcome for stages T1???T2 prostate cancer treated with permanent seed implantation, International Journal of Radiation Oncology*Biology*Physics, vol.67, issue.2, pp.327-333, 2007.
DOI : 10.1016/j.ijrobp.2006.08.056

P. Grimm, J. Blasko, J. Sylvester, R. Meier, and W. Cavanagh, 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy, International Journal of Radiation Oncology*Biology*Physics, vol.51, issue.1, pp.31-40, 2001.
DOI : 10.1016/S0360-3016(01)01601-7

L. Potters, C. Morgenstern, E. Calugaru, P. Fearn, A. Jassal et al., 12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer, The Journal of Urology, vol.179, issue.5, pp.20-24, 2008.
DOI : 10.1016/j.juro.2008.03.133

L. Potters, C. Morgenstern, E. Calugaru, P. Fearn, A. Jassal et al., 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients, J Urol Cosset JM Int J Radiat Oncol Biol Phys, vol.173, issue.714, pp.1562-15661042, 2005.

A. Henry, B. Qaisieh, K. Gould, P. Bownes, J. Smith et al., Outcomes Following Iodine-125 Monotherapy for Localized Prostate Cancer: The Results of Leeds 10-Year Single-Center Brachytherapy Experience, International Journal of Radiation Oncology*Biology*Physics, vol.76, issue.1, pp.50-56, 2010.
DOI : 10.1016/j.ijrobp.2009.01.050

L. Budaus, M. Bolla, A. Bossi, C. Cozzarini, J. Crook et al., Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature Miller NL, Theodorescu D: Health-related quality of life after prostate brachytherapy, Eur Urol BJU Int, vol.2012, issue.944, pp.112-127487, 2004.

M. Keyes, S. Miller, V. Moravan, T. Pickles, M. Liu et al., Urinary Symptom Flare in 712 125I Prostate Brachytherapy Patients: Long-Term Follow-Up, International Journal of Radiation Oncology*Biology*Physics, vol.75, issue.3, pp.75649-655, 2009.
DOI : 10.1016/j.ijrobp.2008.11.043

G. Merrick, W. Butler, J. Lief, and A. Dorsey, Temporal resolution of urinary morbidity following prostate brachytherapy, International Journal of Radiation Oncology*Biology*Physics, vol.47, issue.1, pp.121-128, 2000.
DOI : 10.1016/S0360-3016(99)00525-8

N. Stone and R. Stock, Long-Term Urinary, Sexual, and Rectal Morbidity in Patients Treated with Iodine-125 Prostate Brachytherapy Followed Up for a Minimum of 5 Years, Urology, vol.69, issue.2, pp.338-342, 2007.
DOI : 10.1016/j.urology.2006.10.001

M. Zelefsky, Y. Yamada, P. X. Hunt, M. Cohen, G. Zhang et al., Comparison of Tumor Control and Toxicity Outcomes of High-dose Intensity-modulated Radiotherapy and Brachytherapy for Patients With Favorable Risk Prostate Cancer, Urology, vol.77, issue.4, pp.986-990, 2011.
DOI : 10.1016/j.urology.2010.07.539

S. Liauw, J. Sylvester, C. Morris, J. Blasko, and P. Grimm, Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.3, pp.66669-673, 2006.
DOI : 10.1016/j.ijrobp.2006.05.016

P. Albertsen, J. Hanley, and J. Fine, 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer, JAMA, vol.293, issue.17, pp.2095-2101, 2005.
DOI : 10.1001/jama.293.17.2095

F. Schroder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto et al., Prostate-Cancer Mortality at 11 Years of Follow-up, New England Journal of Medicine, vol.366, issue.11, pp.366981-990, 2012.
DOI : 10.1056/NEJMoa1113135

M. Bul, X. Zhu, R. Valdagni, T. Pickles, Y. Kakehi et al., Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study, European Urology, vol.63, issue.4, pp.597-603, 2013.
DOI : 10.1016/j.eururo.2012.11.005

L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov et al., Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer, Journal of Clinical Oncology, vol.28, issue.1, pp.126-131, 2010.
DOI : 10.1200/JCO.2009.24.2180

R. Godtman, E. Holmberg, A. Khatami, J. Stranne, and J. Hugosson, Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the G??teborg Randomised Population-based Prostate Cancer Screening Trial, European Urology, vol.63, issue.1, pp.101-107, 2013.
DOI : 10.1016/j.eururo.2012.08.066

T. Wilt, M. Brawer, K. Jones, M. Barry, W. Aronson et al., Radical Prostatectomy versus Observation for Localized Prostate Cancer, New England Journal of Medicine, vol.367, issue.3, pp.203-213
DOI : 10.1056/NEJMoa1113162

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429335

J. Beauval, G. Ploussard, M. Soulie, C. Pfister, S. Van-agt et al., Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study, Urology, vol.80, issue.3, pp.656-660
DOI : 10.1016/j.urology.2012.04.051

H. Vargas, O. Akin, A. Afaq, D. Goldman, J. Zheng et al., Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer, The Journal of Urology, vol.188, issue.5, pp.1732-1738
DOI : 10.1016/j.juro.2012.07.024

P. Nguyen, P. Violette, S. Chan, S. Tanguay, W. Kassouf et al., A Panel of TMPRSS2:ERG Fusion Transcript Markers for Urine-Based Prostate Cancer Detection with High Specificity and Sensitivity, European Urology, vol.59, issue.3, pp.59407-414, 2011.
DOI : 10.1016/j.eururo.2010.11.026

S. Loeb, H. Carter, S. Berndt, W. Ricker, E. Schaeffer et al., Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate, J Urol Urology, vol.2013, issue.573, pp.867-870518, 2001.

J. Cohen, R. Miller, J. Ahmed, S. Lotz, M. Baust et al., Ten-Year Biochemical Disease Control for Patients with Prostate Cancer Treated with Cryosurgery as Primary Therapy, Urology, vol.71, issue.3, pp.71515-518, 2008.
DOI : 10.1016/j.urology.2007.09.059

M. Pitman, E. Shapiro, G. Hruby, M. Truesdale, P. Cheetham et al., Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate Primary cryoablation nadir prostate specific antigen and biochemical failure, Prostate J Urol, vol.2012, issue.1823, pp.1802-1808931, 2009.

D. Finley, F. Pouliot, D. Miller, A. Belldegrun, W. Fry et al., Primary and Salvage Cryotherapy for Prostate Cancer, Urologic Clinics of North America, vol.37, issue.1, pp.67-82471, 1954.
DOI : 10.1016/j.ucl.2009.11.007

W. Fry, J. Barnard, E. Fry, R. Krumins, and J. Brennan, Ultrasonic Lesions in the Mammalian Central Nervous System, Science, vol.122, issue.3168, pp.517-518, 1955.
DOI : 10.1126/science.122.3168.517

J. Chapelon, J. Margonari, Y. Theillere, F. Gorry, F. Vernier et al., Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog, European urology, vol.22, issue.2, pp.147-152, 1992.

J. Chapelon, J. Margonari, F. Vernier, F. Gorry, R. Ecochard et al., In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327, Cancer Res, issue.22, pp.526353-6357, 1992.

H. Catez, H. Tonoli-catez, X. Fau-martin, X. Martin, A. Fau-gelet et al., Wholegland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients, Eur Urol, vol.2013, issue.13, pp.302-283800424

S. Vaezy, R. Martin, U. Schmiedl, M. Caps, S. Taylor et al., Liver hemostasis using high-intensity focused ultrasound, Ultrasound in Medicine & Biology, vol.23, issue.9, pp.1413-1420, 1997.
DOI : 10.1016/S0301-5629(97)00143-9

O. Al-bataineh, J. Jenne, and P. Huber, Clinical and future applications of high intensity focused ultrasound in cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.346-353
DOI : 10.1016/j.ctrv.2011.08.004

G. Vallancien, D. Prapotnich, X. Cathelineau, H. Baumert, and F. Rozet, TRANSRECTAL FOCUSED ULTRASOUND COMBINED WITH TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER: FEASIBILITY STUDY, The Journal of Urology, vol.171, issue.6, pp.2265-2267, 2004.
DOI : 10.1097/01.ju.0000124880.35944.58

A. Gelet, J. Chapelon, R. Bouvier, R. Souchon, C. Pangaud et al., Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience, Eur Urol, vol.29, issue.2, pp.174-183, 1996.

A. Gelet, J. Chapelon, R. Bouvier, O. Rouviere, Y. Lasne et al., Transrectal High-Intensity Focused Ultrasound: Minimally Invasive Therapy of Localized Prostate Cancer, Journal of Endourology, vol.14, issue.6, pp.519-528, 2000.
DOI : 10.1089/end.2000.14.519

T. Uchida, N. Sanghvi, T. Gardner, M. Koch, D. Ishii et al., Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report, Urology, vol.59, issue.3, pp.394-398, 2002.
DOI : 10.1016/S0090-4295(01)01624-7

R. Mr, G. Hanks, H. Fau-thames, J. Thames, H. Fau-schellhammer et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure A: First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer, Int J Radiat Oncol Biol Phys BJU Int Eur Urol, vol.1565, issue.666, pp.965-9741058, 2006.

R. Ganzer, H. Fau-fritsche, F. Hm-fau-brandtner, A. Brandtner, A. Fau-brundl et al., Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer, BJU International, vol.24, issue.3, pp.322-329, 2013.
DOI : 10.1111/j.1464-410X.2012.11715.x

T. Uchida, S. Shoji, M. Nakano, S. Hongo, M. Nitta et al., Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience, International Journal of Urology, vol.4, issue.11, pp.16881-886, 2009.
DOI : 10.1111/j.1442-2042.2009.02389.x

T. Uchida, T. Tomonaga, H. Kim, M. Nakano, S. Shoji et al., Improved Outcomes Owing to High-intensity Focused Ultrasound Devices Version-up for the Treatment of Patients with Localized Prostate Cancer Blana A: PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer, J Urol Eur Urol, vol.70, issue.533, pp.547-553, 2008.

R. Ganzer, J. Brundl, D. Koch, W. Wieland, M. Burger et al., Correlation of pretreatment clinical parameters and PSA nadir after high-intensity focused ultrasound (HIFU) for localised prostate cancer, World Journal of Urology, vol.104, issue.8, 2014.
DOI : 10.1007/s00345-014-1289-2

T. Uchida, R. Illing, P. Cathcart, and M. Emberton, To what extent does the prostatespecific antigen nadir predict subsequent treatment failure after transrectal highintensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU international, pp.98537-539, 2006.

S. Hh-fau-jeong, B. , J. Bc-fau-seo, S. , S. Si-fau-jeon et al., Seven years of experience with highintensity focused ultrasound for prostate cancer: advantages and limitations, Prostate, vol.2012, issue.13, pp.721399-1406

P. Jh-fau-farrokhyar, F. Farrokhyar, F. Fau-hassouna, M. , H. Mm-fau-woods et al., Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology, BJU Int, vol.2012, issue.8, pp.1101142-1148

S. Crouzet, X. Fau-rebillard, X. Rebillard, D. Fau-chevallier, D. Chevallier et al., Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 Patients, European Urology, vol.58, issue.4, pp.559-566, 2010.
DOI : 10.1016/j.eururo.2010.06.037

D. Pfeiffer, J. Fau-berger, J. Berger, A. Fau-gross, and A. Gross, Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes, BJU International, vol.180, issue.4, pp.1101702-1707
DOI : 10.1111/j.1464-410X.2012.11375.x

L. Poissonnier, J. Fau-chapelon, C. Jy-fau-rouviere, O. Rouviere, O. Fau-curiel et al., Control of Prostate Cancer by Transrectal HIFU in 227 Patients, European Urology, vol.51, issue.2, pp.51381-387, 2007.
DOI : 10.1016/j.eururo.2006.04.012

URL : https://hal.archives-ouvertes.fr/hal-00397445

S. Thuroff and C. Chaussy, Evolution and Outcomes of 3 MHz High Intensity Focused Ultrasound Therapy for Localized Prostate Cancer During 15 Years, The Journal of Urology, vol.190, issue.2, pp.702-710
DOI : 10.1016/j.juro.2013.02.010

M. Warmuth, T. Fau-johansson, T. Johansson, P. Fau-mad, and P. Mad, Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer, European Urology, vol.58, issue.6, pp.58803-815, 2010.
DOI : 10.1016/j.eururo.2010.09.009

C. Er-fau-cathelineau, X. Cathelineau, X. Fau-thuroff, S. Thuroff, S. Fau-marberger et al., High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer, BJU Int, vol.2012, issue.1109, pp.1228-1242

J. Riviere, J. Bernhard, G. Robert, H. Wallerand, E. Deti et al., Salvage Radiotherapy After High-Intensity Focussed Ultrasound for Recurrent Localised Prostate Cancer, European Urology, vol.58, issue.4, pp.567-573, 2010.
DOI : 10.1016/j.eururo.2010.06.003

G. Levine, D. Amico, A. Berger, P. Clark, P. Eckel et al., Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology, CA: A Cancer Journal for Clinicians, vol.60, issue.3, pp.60194-201, 2010.
DOI : 10.3322/caac.20061

O. Rouviere, N. Girouin, L. Glas, B. Cheikh, A. Gelet et al., Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI, European Radiology, vol.65, issue.6, pp.48-55, 2010.
DOI : 10.1007/s00330-009-1520-5

URL : https://hal.archives-ouvertes.fr/hal-00539311

P. Martino, V. Scattoni, A. Galosi, P. Consonni, C. Trombetta et al., Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU), World Journal of Urology, vol.190, issue.4, pp.29595-605, 2011.
DOI : 10.1007/s00345-011-0687-y

G. Novara, V. Ficarra, S. Mocellin, T. Ahlering, P. Carroll et al., Systematic Review and Meta-analysis of Studies Reporting Oncologic Outcome After Robot-assisted Radical Prostatectomy, European Urology, vol.62, issue.3, pp.62382-404
DOI : 10.1016/j.eururo.2012.05.047

Y. Fujisue, H. Azuma, T. Inamoto, K. Komura, P. Agarwal et al., Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer, World Journal of Urology, vol.17, issue.8, pp.29689-694, 2011.
DOI : 10.1007/s00345-010-0628-1

P. Agarwal, N. Sadetsky, B. Konety, M. Resnick, and P. Carroll, Treatment failure after primary and salvage therapy for prostate cancer, Cancer, vol.173, issue.2, pp.307-314, 2008.
DOI : 10.1002/cncr.23161

J. Stolzenburg, B. Bynens, M. Do, R. Rabenalt, P. Katsakiori et al., Salvage laparoscopic extraperitoneal radical prostatectomy after failed high-intensity focused ultrasound and radiotherapy for localized prostate cancer Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer, Urology World J Urol, vol.70, issue.245, pp.956-960585, 2006.

S. Crouzet, L. Fau-poissonnier, L. Poissonnier, F. Fau-murat, M. Fj-fau-pasticier et al., Traitement du cancer localis?? de la prostate avec l???appareil Ablatherm Imagerie Int??gr??e????: r??sultats carcinologiques et fonctionnels, Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging(R) device], pp.191-197, 2011.
DOI : 10.1016/j.purol.2010.07.005